Cat.No. : AAV00169Z
Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml
Serotype: AAV Serotype 2 Storage: -80 ℃
| Cat. No. | AAV00169Z |
| Description | AAV serotype 2 particles contain Cre recombinase under human synapsin promoter. |
| Serotype | AAV Serotype 2 |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. | |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
RNA N4-acetylcytidine (ac4C) modification is increasingly being recognized as an important aspect of gene regulation. Here, researchers report that N-acetyltransferase 10 protein (NAT10) contributes to the induction and development of neuropathic pain in an ac4C-dependent manner. Peripheral nerve injury increases NAT10 expression and overall ac4C levels in injured dorsal root ganglia (DRGs). This upregulation is triggered by activation of upstream transcription factor 1 (USF1), a transcription factor that binds to the Nat10 promoter. Knockdown or genetic deletion of NAT10 in DRGs abolishes the increase in ac4C sites in Syt9 mRNA and enhanced SYT9 protein, resulting in a significant antinociceptive effect in nerve-injured male mice. In contrast, mimicking NAT10 upregulation in the absence of injury elicits elevations in Syt9 ac4C and SYT9 protein and induces the onset of neuropathic pain-like behaviors. These findings suggest that USF1-regulated NAT10 modulates neuropathic pain by targeting Syt9 ac4C in peripheral nociceptive sensory neurons.
Dot blot analysis using ac4C antibody showed that knockdown of NAT10 by siRNA on day 3 after microinjection (Figure 1a) or knockdown of NAT10 by shRNA on day 4 after microinjection (Figure 1b) in CCI mice inhibited CCI-induced increase in ac4C in L3/4 DRG. Preinjection of AAV2-Syn-Cre on day 21 before surgery abolished the increase in ac4C levels in the L3/4 DRG of CCI Nat10fl/fl mice (Figure 1c). Furthermore, in SUnSET analysis in which nascent proteins were labeled with puromycin via intraperitoneal injection 1 hour before DRG harvest, nerve injury resulted in an increase in nascent proteins in L3/4 DRGs. This increase was significantly reduced by microinjection of Nat10-siRNA in CCI mice but not in randomized controls (Figure 1e,f). Overexpression of NAT10 by microinjection of Lenti-Nat10 but not Lenti-Gfp caused an increase in global ac4C (Figure 1d) and resulted in elevated nascent protein in the L3/4 DRG at day 4 post-injection (Figure 1g,h). Taken together, these data suggest that CCI leads to increased efficiency of de novo protein synthesis as a result of enhanced levels of ac4C, which in turn are because of increased expression of NAT10.
Figure 1. NAT10 promotes enhanced protein synthesis efficiency in the DRG after nerve injury. (Zhang M, et al., 2023)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
AAV2-Syn-Cre has outperformed our expectations in terms of targeting specificity. Its synapsin promoter ensures that Cre recombinase is expressed only in the neurons, minimizing off-target effects.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
